Syngene International Limited has informed the Exchange regarding 'Update on inspection by United States Food & Drug Administration (USFDA)'.

Regulatory & Legal View source PDF Explain this filing

SYNGENE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹655.00

prior close

₹661.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.5%+0.3% vs market

Healthcare Services peers, median of 51sector · industry level+0.2%+0.5% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Smallcap 250 and 0.5 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.6

15m

-1.0

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+0.5+0.3+0.2+0.5

Next day

-1.2-0.2-1.0-0.7-0.5

-1.6-0.4-1.3-0.8-0.8

-4.5-2.3-2.2-2.3-2.2

-3.5-1.7-1.8-2.1-1.4

-3.1-0.9-2.2-2.8-0.4

-0.6+1.4-2.0-0.6-0.0

15d

-2.9+3.0-5.9+2.9-5.8

+2.1+4.5-2.4+5.4-3.3

+1.5-1.9+3.4+6.0-4.5

+0.5+1.0-0.5+7.6-7.2

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US Food and Drug Administration (USFDA) completed a Good Clinical Practices (GCP) compliance inspection of Syngene International's facility at Semicon Park, Bengaluru, from June 9 to June 13, 2025. The inspection concluded successfully with zero observations and no Form 483 was issued. USFDA classified the outcome as 'No Action Indicated' (NAI), the most favourable result, meaning the facility fully meets regulatory requirements. The company reaffirmed its commitment to high operating and compliance standards across all operations.

Likely market impact

Positive for shareholders — a clean USFDA inspection with NAI classification removes regulatory overhang and reinforces confidence in Syngene's clinical research operations, likely supportive of the stock in the near term.